Caribou Biosciences' (CRBU) "Buy" Rating Reaffirmed at HC Wainwright

Caribou Biosciences (NASDAQ:CRBU - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright also issued estimates for Caribou Biosciences' Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.94) EPS.

Other equities research analysts also recently issued research reports about the stock. Bank of America reduced their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Citigroup reduced their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $10.33.

Caribou Biosciences Stock Up 4.0 %

Shares of NASDAQ:CRBU traded up $0.04 during midday trading on Wednesday, hitting $1.04. 1,140,789 shares of the stock traded hands, compared to its average volume of 1,598,349. The stock has a market capitalization of $96.73 million, a PE ratio of -0.63 and a beta of 2.34. The business's 50 day moving average is $1.29 and its two-hundred day moving average is $1.74. Caribou Biosciences has a one year low of $0.95 and a one year high of $5.62.

Remove Ads

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. As a group, sell-side analysts forecast that Caribou Biosciences will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Caribou Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new stake in Caribou Biosciences in the 4th quarter worth approximately $222,000. Two Sigma Investments LP grew its position in Caribou Biosciences by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company's stock worth $1,779,000 after purchasing an additional 214,239 shares during the period. Two Sigma Advisers LP grew its position in Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock worth $2,338,000 after purchasing an additional 416,600 shares during the period. Nuveen Asset Management LLC grew its position in Caribou Biosciences by 23.6% in the 4th quarter. Nuveen Asset Management LLC now owns 330,831 shares of the company's stock worth $526,000 after purchasing an additional 63,096 shares during the period. Finally, Millennium Management LLC grew its position in Caribou Biosciences by 52.9% in the 4th quarter. Millennium Management LLC now owns 859,825 shares of the company's stock worth $1,367,000 after purchasing an additional 297,351 shares during the period. Institutional investors own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.